New Orleans, LA (March 6, 2023) – RCE Technologies, Inc’s groundbreaking study titled “A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction” was presented at the American College of Cardiology – Late Breaking Clinical Trials on March 6, 2023. The presentation was delivered center stage by Dr. Partho Sengupta, Henry Rutgers Professor of Cardiology and Division Chief of Cardiology at the Rutgers Robert Wood Johnson Medical Center.
The study, which has also been published in the prestigious European Society of Cardiology, focuses on the development of a wrist-worn transdermal troponin-I-sensor for the assessment of acute myocardial infarction. The sensor enables real-time detection of troponin-I levels, a key biomarker of heart damage, through a non-invasive modality that does not require any blood sampling.
“This is a major breakthrough, and posits the potential for improvement in the diagnosis and management of heart attacks,” said Atandra Burman, Founder & CEO, RCE. “Time is Muscle. With this wrist-worn sensor, we can provide real-time monitoring of heart muscle injury that can empower clinicians in a much needed timely intervention in patients with an impending heart attack.”
RCE.ai, an AI based med tech company works towards the early detection of heart attacks. We have re-imagined the way cardiac proteins are monitored in the blood using a non-invasive transdermal technique. The instant reporting of one such protein, cardiac Troponin empowers emergency medicine physicians and cardiologists in the early assessment and appropriate risk stratification of patients presenting with chest pain. We currently are conducting clinical studies and undertaking premarket efforts.